Unerwünschte Arzneireaktionen an der Haut

R. A. Rupec; S. Boneberger; T. Ruzicka

doi:10.1055/s-2007-993120

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2007; 132(50): 2685-2694
DOI: 10.1055/s-2007-993120

CME-Beitrag | Review article

Dermatologie, Pharmakologie
© Georg Thieme Verlag KG Stuttgart · New York

Unerwünschte Arzneireaktionen an der Haut

Coutaneous drug reactionsR. A. Rupec¹ , S. Boneberger¹ , T. Ruzicka¹

¹Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität München

Abstract

Schlüsselwörter

unerwünschte Arzneireaktion - Exantheme - Hypersensitivitätssyndrom - Stevens-Johnson-Syndrom - toxische epidermale Nekrolyse - akute generalisierte exanthematische Pustulose

Key words

adverse drug reaction - exanthema - drug rash with eosinophilia and systemic symptoms - Stevens-Johnson syndrome - toxic epidermal necrolysis - acute generalized exanthematous pustulosis

Full Text

References

Literatur

1 Allam J P, Paus T, Reichel C, Bieber T, Novak N. DRESS syndrome associated with carbamazepine and phenytoin. Eur J Dermatol. 2004; 14 339-342
2 Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986; 256 3358-3363
3 Brockow K, Romano A, Blanca M. et al . General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002; 57 45-51
4 Brooks S L. Lichenoid reaction of oral mucosa and skin to methyldopa. J Oral Med. 1982; 37 42-44
5 Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007; 357 514-515
6 Calista D, Morri M. Lichen planus induced by hepatitis B vaccination: a new case and review of the literature. Int J Dermatol. 2004; 43 562-564
7 de Groot A C. Patch testing. 2nd ed. Elsevier Amsterdam 1994
8 Descamps V, Valance A, Edlinger C. et al . Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001; 137 301-304
9 Duran I, Hotte S J, Hirte H. et al . Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2007; 13 4849-4857
10 Gotlib V, Khaled S, Lapko I, Mar N, Saif M W. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006; 17 1227-1229
11 Gould J W, Mercurio M G, Elmets C A. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. 1995; 33 551-573
12 Guenther C H, Wozel G, Laske J, Aschoff R, Meurer M. Macular exanthema due to fumaric acid esters. Ann Pharmacother. 2003; 37 234-236
13 Guijarro G uijarro B, Lopez S anchez AF. Lichenoid reaction caused by Clopidogrel, a new anti-platelet drug. Med Oral. 2003; 8 33-37
14 Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol. 2005; 153 849-851
15 Herfs H, Schirren C G, Przybilla B, Plewig G. Das „Baboon-Syndrom”. Eine besondere Manifestation einer hämatogenen Kontaktreaktion. Hautarzt. 1993; 44 466-469
16 Jamali M, El O uazzani T, Zouhair K, Lakhdar H. Carbamazepine hypersensitivity syndrome associated with cytomegalovirus reactivation. Ann Dermatol Venereol. 2007; 134 72-73
17 Komericki P, Grims R, Kranke B, Aberer W. Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol. 2007; 57 718-721
18 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279 1200-1205
19 Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo R M, Delaporte E. Manifestations cutanées observées au cours d’un traitement par anti-TNF a: 11 observations. Ann Dermatol Venereol. 2007; 134 337-342
20 Lim D S, Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology. 2002; 205 169-171
21 Limentani S A, Brufsky A M, Erban J K, Jahanzeb M, Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol. 2007; 25 1232-1238
22 Litt J Z. Drug eruption reference manual. 12th ed. Taylor and Francis London and New York 2006
23 Mittmann N, Chan B C, Knowles S, Shear N H. IVIG for the treatment of toxic epidermal necrolysis. Skin Therapy Lett. 2007; 12 7-9
24 Mockenhaupt M. Schwere Arzneimittelreaktionen der Haut. Klinik und Epidemiologie. Hautarzt. 2005; 56 24-31
25 Organization W H. International drug monitoring: The role of the hospital. In, Technical Report Series No 425. World Health Organization Geneva, Switzerland 1966
26 Pereira F A, Mudgil A V, Rosmarin D M. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007; 56 181-200
27 Ring J, Darsow U. Idiopathic anaphylaxis. Curr Allergy Asthma Rep. 2002; 2 40-45
28 Roujeau J C, Bioulac-Sage P, Bourseau C. et al . Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991; 127 1333-1338
29 Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007; 17 201-208
30 Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol. 2002; 2 317-323
31 Stern R S. Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol. 2000; 136 410-411
32 Van Doorn R, Kirtschig G, Scheffer E, Stoof T J, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002; 147 598-601
33 Yasuda S, Mizuno N, Kawabe Y, Sakakibara S. Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine. Photodermatol. 1988; 5 206-210
34 Zoller A, Schad S G, Gross G E. Erlotinib-associated skin reactions - case report and proposal for classification. Br J Dermatol. 2006; 155 1293-1295
35 Zürcher K, Krebs A. Cutaneous drug reactions: an integral synopsis of today’s systemic drugs. 2nd ed. Karger Freiburg i. Br. 1998

Prof. Dr. med. Dr. h. c. Thomas Ruzicka

Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität München

Frauenlobstr. 9 - 11

80337 München

Phone: 089/5160-6001

Fax: 089/5160-6002

Email: thomas.ruzicka@med.uni-muenchen.de